Modality
ADC
MOA
FcRni
Target
GPRC5D
Pathway
Cell Cycle
Bladder Ca
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
~Feb 2019
→ ~May 2020
Phase 3
~Aug 2020
→ ~Nov 2021
NDA/BLA
Feb 2022
→ Mar 2026
NDA/BLACurrent
NCT04780482
864 pts·Bladder Ca
2022-02→2026-03·Completed
864 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-256d agoPh3 Readout· Bladder Ca
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-03-25 · 6d ago
Bladder Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04780482 | NDA/BLA | Bladder Ca | Completed | 864 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D |